Medical Device News Magazine

Monday, May 23, 2022

Ph: 561.316.3330

Home

Press Releases

About

Editorial

Advertise

Health/Lifestyle

Articles

Contact

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

Market Reports

FDA

Executives

Funding

Acquisitions

Non Profits

Hospitals

Subscribe

Biotechnology News Magazine

Filterlex Medical Successfully Completes First-In-Human Study for CAPTIS® Full-Body Embolic Protection Device

Cardiovascular study results to be presented by Prof. Ran Kornowski, Director of the Cardiology Center, Rabin Medical Center at the EuroPCR 2022 conference in May

Filterlex Medical Ltd., a cardiovascular medical device startup, announced today that it has completed its CAPTIS First-In-Human (FIH) study. Study results will be presented by Prof. Ran Kornowski, Director of the Cardiology Center at Rabin Medical Center during the EuroPCR conference, 17-20 May, 2022.

- Advertisement -

The CAPTIS is a next-generation, full-body embolic protection device to reduce the risk of stroke and other complications during left-heart procedures.

The FIH study was designed to demonstrate the safety and feasibility of the CAPTIS device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR). The study, including 20 patients, took place in two leading hospitals in Israel, Wolfson Medical Center and Rabin Medical Center (Beilinson Hospital).

During catheter-based procedures, such as TAVR, embolic particles are often released into the blood stream and may cause neurological deficiencies, extending from cognitive impairment to debilitating stroke.

The CAPTIS device is easily and intuitively deployed and retrieved. It is securely positioned in the aorta, protecting its surface, while facilitating a seamless TAVR procedure. The CAPTIS uniquely requires no additional arterial access and does not interfere with the procedure workflow.

“The unique design of the CAPTIS was created out of a deep understanding of the TAVR procedure and commitment to protect patients’ brain and kidneys. We look forward to presenting these promising FIH results later this month,” said Co-founder and CMO, Dr. Giora Weisz.

Sigal Eli, Filterlex Medical Co-founder and CEO added: “We are thrilled about having reached this milestone. With our recent successful US $6 million series A1 investment and €7 million investment commitment from the European Innovation Council, our strategic plan is being executed and we remain committed to delivering a much-needed embolic protection device to the millions at risk during TAVR.”

Filterlex Medical Ltd. is a cardiovascular medical device startup developing the CAPTIS®, a full-body embolic protection device. In 2016, Filterlex joined Alon MedTech Ventures incubator, owned by Dr. Shimon Eckhouse, a leading entrepreneur and investor in the field of medical devices. The company’s founders have vast clinical knowledge and extensive experience in medical device development, commercialization, and marketing.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
spot_img

Other News of Interest

Executives on the Move

By using this website you agree to accept Medical Device News Magazine Privacy Policy